Thu, September 16, 2010
Wed, September 15, 2010
[ Wed, Sep 15th 2010 ] - Market Wire
Qtrax Beta Available in India
Tue, September 14, 2010
Mon, September 13, 2010
Sun, September 12, 2010
Fri, September 10, 2010
Thu, September 9, 2010
Wed, September 8, 2010
Tue, September 7, 2010
Sat, September 4, 2010
[ Sat, Sep 04th 2010 ] - Market Wire
Transdel Pharmaceuticals
Fri, September 3, 2010
Thu, September 2, 2010
Wed, September 1, 2010
Tue, August 31, 2010
Mon, August 30, 2010
Sun, August 29, 2010
Fri, August 27, 2010
[ Fri, Aug 27th 2010 ] - Market Wire
?????????????????????
Thu, August 26, 2010

Inspire Announces Webcast of Presentation at Stifel Nicolaus Healthcare Conference


//health-fitness.news-articles.net/content/2010/ .. on-at-stifel-nicolaus-healthcare-conference.html
Published in Health and Fitness on Wednesday, September 8th 2010 at 6:52 GMT by Market Wire   Print publication without navigation


DURHAM, N.C.--([ BUSINESS WIRE ])--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Adrian Adams, President and CEO, will present at the Stifel Nicolaus 2010 Healthcare Conference on Wednesday, September 15, 2010 at 2:40 pm ET in Boston, MA.

The webcast of the presentation will be available on Inspirea™s web site at [ www.inspirepharm.com ]. An archived version of the webcast presentation will also be available through this link for a limited time following the conference.

About Inspire

Inspire is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspirea™s goal is to build and commercialize a sustainable portfolio of innovative new products based on its technical, scientific and commercial expertise. Inspirea™s clinical pipeline includes denufosol tetrasodium for cystic fibrosis in Phase 3 development and AZASITE®(azithromycin ophthalmic solution) 1% for blepharitis in Phase 2 development. Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% for dry eye. For more information, visit [ www.inspirepharm.com ].


Publication Contributing Sources